-
Something wrong with this record ?
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
AM. Oza, A. Lisyanskaya, A. Fedenko, AC. de Melo, Y. Shparyk, I. Rakhmatullina, I. Bondarenko, N. Colombo, V. Svintsitskiy, L. Biela, M. Nechaeva, D. Lorusso, G. Scambia, D. Cibula, R. Póka, A. Oaknin, T. Safra, B. Mackowiak-Matejczyk, L. Ma, D....
Language English Country England, Great Britain
Document type Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Multicenter Study, Comparative Study
NLK
ProQuest Central
from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest)
from 2000-09-01 to 2 months ago
Public Health Database (ProQuest)
from 2000-09-01 to 2 months ago
- MeSH
- Progression-Free Survival MeSH
- Adult MeSH
- Indoles * therapeutic use administration & dosage adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local * drug therapy genetics pathology MeSH
- Mutation * MeSH
- Ovarian Neoplasms * drug therapy genetics pathology mortality MeSH
- Paclitaxel administration & dosage adverse effects MeSH
- Poly(ADP-ribose) Polymerase Inhibitors therapeutic use adverse effects administration & dosage MeSH
- BRCA1 Protein * genetics MeSH
- BRCA2 Protein * genetics MeSH
- Antineoplastic Combined Chemotherapy Protocols * therapeutic use MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial, Phase III MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
BACKGROUND: In the ARIEL4 trial of rucaparib versus standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma, the primary endpoint was met, showing improved investigator-assessed progression-free survival with rucaparib. Here, we present the final overall survival analysis of the trial and other post-progression outcomes. METHODS: This open-label, randomised, controlled phase 3 trial was done at 64 hospitals and cancer centres in 12 countries, including Brazil, Canada, Czech Republic, Hungary, Israel, Italy, Poland, Russia, Spain, Ukraine, the UK, and the USA. Eligible patients were women aged 18 or older with BRCA1 or BRCA2-mutated ovarian carcinoma and had received at least two previous chemotherapy regimens. Patients had to have evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) criteria and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (2:1) using an interactive response technology and block randomisation (block size of six) and stratified by progression-free interval after the most recent platinum-containing therapy to receive oral rucaparib (600 mg twice daily administered in 28-day cycles) or chemotherapy on the basis of platinum-sensitivity status. In the chemotherapy group, patients with platinum-resistant disease (progression-free interval ≥1 to <6 months) or partially platinum-sensitive disease (progression-free interval ≥6 to <12 months) received weekly paclitaxel (starting dose 60-80 mg/m2 on days 1, 8, and 15). Patients with fully platinum-sensitive disease (progression-free interval ≥12 months) received the investigator's choice of platinum-based chemotherapy (single-agent cisplatin or carboplatin, or platinum-doublet chemotherapy), in 21-day or 28-day cycles. The primary endpoint (previously reported) was investigator-assessed progression-free survival, assessed in the efficacy population (all randomly assigned patients with deleterious BRCA1 or BRCA2 mutations without reversion mutations) and in the intention-to-treat population (all randomly assigned patients). Overall survival was a prespecified secondary endpoint and was analysed in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned study treatment. The cutoff date was April 10, 2022. This study is registered with ClinicalTrials.gov, NCT02855944; enrolment is complete and the study is closed. FINDINGS: Between March 1, 2017, and Sept 24, 2020, 349 eligible patients were randomly assigned to receive rucaparib (n=233) or chemotherapy (n=116). 332 (95%) of 349 patients were white and 17 (5%) patients were other or of unknown race. In the chemotherapy group, 80 (69%) of 116 patients crossed over to receive rucaparib. Median follow-up was 41·2 months (IQR 37·8-44·6). At data cutoff for this final analysis (April 10, 2022), 244 (70%) of 349 patients had died: 167 (72%) of 233 in the rucaparib group and 77 (66%) of 116 in the rucaparib group. Median overall survival was 19·4 months (95% CI 15·2-23·6) in the rucaparib group versus 25·4 months (21·4-27·6) in the chemotherapy group (hazard ratio 1·3 [95% CI 1·0-1·7], p=0·047). No new safety signals were observed, including during crossover to rucaparib. The most common grade 3-4 adverse events across treatment groups included anaemia or decreased haemoglobin (reported in 59 [25%] of 232 patients in the rucaparib group and seven [6%] of 113 in the chemotherapy group), and neutropenia or decreased neutrophil count (in 26 [11%] of 232 in the rucaparib group and 16 [14%] of 113 patients in the chemotherapy group). Serious adverse events were reported in 66 (28%) of 232 patients in the rucaparib group and 14 (12%) of 113 patients in the chemotherapy group. Ten treatment-related deaths were reported in the rucaparib group, two of which were linked to judged to be related to rucaparib (cardiac disorder and myelodysplastic syndrome), and one death related to treatment was reported in the chemotherapy group, with no specific cause linked to the treatment. INTERPRETATION: These data highlight the need for a better understanding of the most appropriate treatment for patients who have progressed on a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, and the optimal sequencing of chemotherapy and PARP inhibitors in advanced ovarian cancer. FUNDING: Clovis Oncology.
Bialostockie Centrum Onkologii im Marii Sklodowskiej Curie Białystok Poland
Biostatistics Clovis Oncology Boulder CO USA
Clinical Development Clovis Oncology Boulder CO USA
Clinical Operations Clovis Oncology Boulder CO USA
Clinical Research Center Instituto de Oncologia do Parana Curitiba Brazil
Department of Chemotherapy Arkhangelsk Clinical Oncological Dispensary Arkhangelsk Russia
Department of Chemotherapy Lviv Regional Oncology Dispensary Lviv Ukraine
Department of Chemotherapy N N Blokhin Russian Cancer Research Center Moscow Russia
Department of Obstetrics and Gynecology Clinical Center University of Debrecen Debrecen Hungary
Department of Oncology and Medical Radiology Dnipropetrovsk Medical Academy Dnipro Ukraine
Department of Oncology Guy's and St Thomas' NHS Foundation Trust London UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009995
- 003
- CZ-PrNML
- 005
- 20250429135108.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(24)00674-0 $2 doi
- 035 __
- $a (PubMed)39914419
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Oza, Amit M $u Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Electronic address: amit.oza@uhn.ca
- 245 10
- $a Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial / $c AM. Oza, A. Lisyanskaya, A. Fedenko, AC. de Melo, Y. Shparyk, I. Rakhmatullina, I. Bondarenko, N. Colombo, V. Svintsitskiy, L. Biela, M. Nechaeva, D. Lorusso, G. Scambia, D. Cibula, R. Póka, A. Oaknin, T. Safra, B. Mackowiak-Matejczyk, L. Ma, D. Thomas, KK. Lin, K. McLachlan, S. Goble, R. Kristeleit
- 520 9_
- $a BACKGROUND: In the ARIEL4 trial of rucaparib versus standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma, the primary endpoint was met, showing improved investigator-assessed progression-free survival with rucaparib. Here, we present the final overall survival analysis of the trial and other post-progression outcomes. METHODS: This open-label, randomised, controlled phase 3 trial was done at 64 hospitals and cancer centres in 12 countries, including Brazil, Canada, Czech Republic, Hungary, Israel, Italy, Poland, Russia, Spain, Ukraine, the UK, and the USA. Eligible patients were women aged 18 or older with BRCA1 or BRCA2-mutated ovarian carcinoma and had received at least two previous chemotherapy regimens. Patients had to have evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) criteria and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (2:1) using an interactive response technology and block randomisation (block size of six) and stratified by progression-free interval after the most recent platinum-containing therapy to receive oral rucaparib (600 mg twice daily administered in 28-day cycles) or chemotherapy on the basis of platinum-sensitivity status. In the chemotherapy group, patients with platinum-resistant disease (progression-free interval ≥1 to <6 months) or partially platinum-sensitive disease (progression-free interval ≥6 to <12 months) received weekly paclitaxel (starting dose 60-80 mg/m2 on days 1, 8, and 15). Patients with fully platinum-sensitive disease (progression-free interval ≥12 months) received the investigator's choice of platinum-based chemotherapy (single-agent cisplatin or carboplatin, or platinum-doublet chemotherapy), in 21-day or 28-day cycles. The primary endpoint (previously reported) was investigator-assessed progression-free survival, assessed in the efficacy population (all randomly assigned patients with deleterious BRCA1 or BRCA2 mutations without reversion mutations) and in the intention-to-treat population (all randomly assigned patients). Overall survival was a prespecified secondary endpoint and was analysed in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned study treatment. The cutoff date was April 10, 2022. This study is registered with ClinicalTrials.gov, NCT02855944; enrolment is complete and the study is closed. FINDINGS: Between March 1, 2017, and Sept 24, 2020, 349 eligible patients were randomly assigned to receive rucaparib (n=233) or chemotherapy (n=116). 332 (95%) of 349 patients were white and 17 (5%) patients were other or of unknown race. In the chemotherapy group, 80 (69%) of 116 patients crossed over to receive rucaparib. Median follow-up was 41·2 months (IQR 37·8-44·6). At data cutoff for this final analysis (April 10, 2022), 244 (70%) of 349 patients had died: 167 (72%) of 233 in the rucaparib group and 77 (66%) of 116 in the rucaparib group. Median overall survival was 19·4 months (95% CI 15·2-23·6) in the rucaparib group versus 25·4 months (21·4-27·6) in the chemotherapy group (hazard ratio 1·3 [95% CI 1·0-1·7], p=0·047). No new safety signals were observed, including during crossover to rucaparib. The most common grade 3-4 adverse events across treatment groups included anaemia or decreased haemoglobin (reported in 59 [25%] of 232 patients in the rucaparib group and seven [6%] of 113 in the chemotherapy group), and neutropenia or decreased neutrophil count (in 26 [11%] of 232 in the rucaparib group and 16 [14%] of 113 patients in the chemotherapy group). Serious adverse events were reported in 66 (28%) of 232 patients in the rucaparib group and 14 (12%) of 113 patients in the chemotherapy group. Ten treatment-related deaths were reported in the rucaparib group, two of which were linked to judged to be related to rucaparib (cardiac disorder and myelodysplastic syndrome), and one death related to treatment was reported in the chemotherapy group, with no specific cause linked to the treatment. INTERPRETATION: These data highlight the need for a better understanding of the most appropriate treatment for patients who have progressed on a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, and the optimal sequencing of chemotherapy and PARP inhibitors in advanced ovarian cancer. FUNDING: Clovis Oncology.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a indoly $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D007211
- 650 12
- $a nádory vaječníků $x farmakoterapie $x genetika $x patologie $x mortalita $7 D010051
- 650 12
- $a protein BRCA1 $x genetika $7 D019313
- 650 12
- $a protein BRCA2 $x genetika $7 D024682
- 650 12
- $a lokální recidiva nádoru $x farmakoterapie $x genetika $x patologie $7 D009364
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a PARP inhibitory $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D000067856
- 650 _2
- $a paclitaxel $x aplikace a dávkování $x škodlivé účinky $7 D017239
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a srovnávací studie $7 D003160
- 700 1_
- $a Lisyanskaya, Alla $u Department of Gynaecological Oncology, Saint Petersburg City Oncological Dispensary, Saint Petersburg, Russia
- 700 1_
- $a Fedenko, Alexander $u Department of Chemotherapy, N N Blokhin Russian Cancer Research Center, Moscow, Russia
- 700 1_
- $a de Melo, Andreia Cristina $u Division of Clinical Research and Technological Development, National Cancer Institute, Rio de Janeiro, Brazil
- 700 1_
- $a Shparyk, Yaroslav $u Department of Chemotherapy, Lviv Regional Oncology Dispensary, Lviv, Ukraine
- 700 1_
- $a Rakhmatullina, Irina $u Department of Oncology with IAPE Oncology and Pathologic Anatomy Course, Bashkir State Medical University, Ufa, Russia
- 700 1_
- $a Bondarenko, Igor $u Department of Oncology and Medical Radiology, Dnipropetrovsk Medical Academy, Dnipro, Ukraine
- 700 1_
- $a Colombo, Nicoletta $u Gynecologic Cancer Program, University of Milan-Bicocca and European Institute of Oncology, IRCCS, Milan, Italy
- 700 1_
- $a Svintsitskiy, Valentyn $u Department of Oncogynecology, National Cancer Institute of the Ministry of Health of Ukraine, Kyiv, Ukraine
- 700 1_
- $a Biela, Luciano $u Clinical Research Center, Instituto de Oncologia do Parana, Curitiba, Brazil
- 700 1_
- $a Nechaeva, Marina $u Department of Chemotherapy, Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Russia
- 700 1_
- $a Lorusso, Domenica $u Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies and Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
- 700 1_
- $a Scambia, Giovanni $u Gynecologic Oncology Unit, Fondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy
- 700 1_
- $a Cibula, David $u Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University a General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Póka, Róbert $u Department of Obstetrics and Gynecology, Clinical Center, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Oaknin, Ana $u Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
- 700 1_
- $a Safra, Tamar $u Department of Oncology, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- 700 1_
- $a Mackowiak-Matejczyk, Beata $u Bialostockie Centrum Onkologii im Marii Sklodowskiej-Curie, Białystok, Poland
- 700 1_
- $a Ma, Ling $u Rocky Mountain Cancer Centers, Lakewood, CO, USA
- 700 1_
- $a Thomas, Daleen $u Clinical Operations, Clovis Oncology, Boulder, CO, USA
- 700 1_
- $a Lin, Kevin K $u Molecular Diagnostics, Clovis Oncology, Boulder, CO, USA
- 700 1_
- $a McLachlan, Karen $u Clinical Development, Clovis Oncology, Boulder, CO, USA
- 700 1_
- $a Goble, Sandra $u Biostatistics, Clovis Oncology, Boulder, CO, USA
- 700 1_
- $a Kristeleit, Rebecca $u Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK
- 773 0_
- $w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 26, č. 2 (2025), s. 249-264
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39914419 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429135103 $b ABA008
- 999 __
- $a ok $b bmc $g 2311393 $s 1247076
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 26 $c 2 $d 249-264 $e - $i 1474-5488 $m Lancet oncology $n Lancet Oncol $x MED00011558
- LZP __
- $a Pubmed-20250415
